These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26049360)

  • 1. [Significant decline in the rate of cardiovascular incidents].
    Wedekind S
    MMW Fortschr Med; 2015 Jun; 157(11):66. PubMed ID: 26049360
    [No Abstract]   [Full Text] [Related]  

  • 2. Lowering LDL cholesterol is good, but how and in whom?
    Stone NJ; Lloyd-Jones DM
    N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of the change in the Framingham Risk Score calculator between the 2006 and 2009 Canadian lipid guidelines.
    Armstrong DW; Brouillard D; Matangi MF
    Can J Cardiol; 2011; 27(2):167-70. PubMed ID: 21459264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 Inhibitors and Cardiovascular Events.
    Sabatine MS; Wasserman SM; Stein EA
    N Engl J Med; 2015 Aug; 373(8):774-5. PubMed ID: 26295078
    [No Abstract]   [Full Text] [Related]  

  • 5. PCSK9 Inhibitors and Cardiovascular Events.
    Goemann IM; Londero TM; Dora JM
    N Engl J Med; 2015 Aug; 373(8):773-4. PubMed ID: 26287856
    [No Abstract]   [Full Text] [Related]  

  • 6. PCSK9 Inhibitors and Cardiovascular Events.
    Auer J; Berent R; Primus C
    N Engl J Med; 2015 Aug; 373(8):773. PubMed ID: 26287855
    [No Abstract]   [Full Text] [Related]  

  • 7. PCSK9 Inhibitors and Cardiovascular Events.
    Robinson JG; Kastelein JJ
    N Engl J Med; 2015 Aug; 373(8):774. PubMed ID: 26287854
    [No Abstract]   [Full Text] [Related]  

  • 8. [Lowering LDL cholesterol frequently does not adhere to guidelines. Also regard intestinal cholesterol source].
    MMW Fortschr Med; 2005 Jun; 147(23):48-9. PubMed ID: 15981908
    [No Abstract]   [Full Text] [Related]  

  • 9. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
    Mayor S
    BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
    [No Abstract]   [Full Text] [Related]  

  • 10. Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.
    Huynh K
    Nat Rev Cardiol; 2015 May; 12(5):261. PubMed ID: 25824512
    [No Abstract]   [Full Text] [Related]  

  • 11. [Is lower better? Is lowest the best?].
    Tokgözoğlu L
    Turk Kardiyol Dern Ars; 2017 Apr; 45(3):211-213. PubMed ID: 28429686
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
    Sabatine MS; Giugliano RP; Wiviott SD; Raal FJ; Blom DJ; Robinson J; Ballantyne CM; Somaratne R; Legg J; Wasserman SM; Scott R; Koren MJ; Stein EA;
    N Engl J Med; 2015 Apr; 372(16):1500-9. PubMed ID: 25773607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk patients are often insufficiently treated. LDL cholesterol to be held down even more vigorously].
    MMW Fortschr Med; 2004 Oct; 146(44):56-7. PubMed ID: 15566253
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
    N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk of cardiovascular complications cut in half?].
    Einecke D
    MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic.
    Kiburg KV; Ward GM; O'Neal DN; MacIsaac RJ
    Intern Med J; 2018 Feb; 48(2):201-204. PubMed ID: 29415350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid Management Steps Forward.
    Siegel JA
    J S C Med Assoc; 2015 Dec-2016 Jan; 111(4):122-5. PubMed ID: 27141703
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis.
    Krittanawong C; Kitai T; Zhang H; Sun T
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):645-646. PubMed ID: 27830381
    [No Abstract]   [Full Text] [Related]  

  • 19. PCSK9 Inhibitors: From Innovation to Sustainable Clinical Application.
    Lekuona I
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):996-998. PubMed ID: 30150140
    [No Abstract]   [Full Text] [Related]  

  • 20. [Will the LDL target value soon become zero?].
    Red
    MMW Fortschr Med; 2016 May; 158(10):87. PubMed ID: 27382842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.